Several companies have reported their fourth quarter and full year 2024 financial results. Constellation, NeoGenomics, and MasterBrand are among those that released their results. Hillman Solutions reported an adjusted EPS of $0.10, missing the estimate of $0.11, with sales of $349.56 million also falling short of the $350.28 million estimate. Blackbaud's adjusted EPS was $1.08, beating the estimate of $1.06, but sales of $302.232 million missed the $303.734 million estimate. Donnelley Financial Solutions reported an adjusted EPS of $0.40, missing the $0.49 estimate, with sales of $156.300 million below the $169.187 million estimate. Axsome Therapeutics achieved a GAAP EPS of $(1.54), missing the $(1.03) estimate, while sales of $118.77 million beat the $117.64 million estimate. Halozyme Therapeutics reported an adjusted EPS of $1.26, surpassing the $1.16 estimate, with sales of $298.00 million also beating the $288.24 million estimate. Other notable reports include RB Global with an adjusted EPS of $0.95 and sales of $1.142 billion, both exceeding estimates, and International Flavors & Fragrances, which reported an adjusted EPS of $0.97 and sales of $2.771 billion, both beating estimates. Cinemark Holdings reported a record fourth-quarter revenue of $814.3 million, an increase of 27.5% year-over-year, and reinstated its dividend.